Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Featured sites

Sites that work closely with us on this trial

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for patients who are hospitalized due to a severe viral lung infection and require extra oxygen to help them breathe. The treatment being tested is called Tozorakimab, also known by its code name MEDI3506. It is a solution that is given through an injection into the veins. The study will compare the effects of Tozorakimab with a placebo to see how well it works in preventing serious outcomes like death or the need for advanced breathing support by Day 28 of the study.

The purpose of this study is to evaluate the safety and effectiveness of Tozorakimab in helping patients recover from severe viral lung infections. Participants in the study will receive either the Tozorakimab treatment or a placebo, in addition to the standard care they are already receiving. The study will monitor the participants over a period of time to see how many days they are alive and free from needing intensive care or extra oxygen, as well as other health outcomes.

Throughout the study, researchers will collect information on various health measures, such as the number of days participants are alive and not in the intensive care unit, and the time it takes for them to recover enough to stop needing extra oxygen. The study aims to provide valuable insights into how Tozorakimab can help improve the health and recovery of patients with severe viral lung infections.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment

    Upon joining the study, eligibility is confirmed based on specific criteria. Participants must be adults aged 18 or older, hospitalized with a viral lung infection, and require supplemental oxygen due to low blood oxygen levels.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either tozorakimab or a placebo. This process is double-blind, meaning neither the participants nor the researchers know who receives the actual medication.

  3. Step 3

    Treatment administration

    Tozorakimab is administered as a solution for injection through an intravenous route. The frequency and dosage are determined by the study protocol and are administered by healthcare professionals.

  4. Step 4

    Monitoring and assessments

    Participants are monitored for 28 days to evaluate the effect of the treatment. The primary focus is on preventing death or the need for advanced respiratory support, such as mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

    Secondary assessments include survival rates up to 60 days, time spent outside the intensive care unit (ICU), and days without the need for supplemental oxygen.

  5. Step 5

    Follow-up

    Participants continue to be observed for any long-term effects or outcomes related to the treatment. This includes tracking survival rates, time to discharge, and any development of antibodies against the drug.

Who can join the trial?

6 criteria

  • Participants must be 18 years or older at the time they sign the consent form.
  • Participants must be hospitalized due to a viral lung infection.
  • Participants must have low oxygen levels in their blood, which requires treatment with extra oxygen. Low oxygen levels are defined as:
    • Blood oxygen saturation (SpO2) of 90% or less, or
    • Blood oxygen saturation (SpO2) of 92% or less along with one or both of the following:
      • Chest X-ray or CT scan showing signs of a viral lung infection, as judged by the doctor.
      • Using extra muscles to breathe or having a breathing rate of more than 22 breaths per minute.
      • Participants must still have low oxygen levels at the time they are randomly assigned to a treatment group, requiring extra oxygen treatment.

Who cannot join the trial?

3 criteria

  • Patients with **severe viral lung infections** cannot participate. This means if you have a serious infection in your lungs caused by a virus, you are not eligible.
  • Patients who do not require **supplemental oxygen** are excluded. This means if you do not need extra oxygen to help you breathe, you cannot join the study.
  • Patients who are already on **IMV/ECMO** are not eligible. IMV stands for **invasive mechanical ventilation**, which is a machine that helps you breathe. ECMO stands for **extracorporeal membrane oxygenation**, which is a machine that helps your heart and lungs work.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Tozorakimab (MEDI3506) is a medication being studied for its potential to help patients who are hospitalized with viral lung infections and need extra oxygen. The goal of using this medication is to see if it can prevent the patient's condition from getting worse, such as needing a machine to help them breathe or preventing death within 28 days of treatment.

What is already known about the treatment

Tozorakimab – This medication is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating severe viral lung infections. It is in the experimental phase and not yet widely available in medical practice. The main therapeutic indication is for patients hospitalized with viral lung infections who require supplemental oxygen. Tozorakimab works by targeting specific proteins involved in the inflammatory response, potentially reducing lung inflammation and preventing disease progression. It is classified as a monoclonal antibody, a type of medication designed to interact with specific molecules in the body to modulate immune responses.

Investigated diseases

Severe viral lung infections – These infections occur when viruses invade the lungs, leading to inflammation and difficulty in breathing. The condition can cause symptoms such as coughing, fever, and shortness of breath. As the infection progresses, it may result in the need for supplemental oxygen to maintain adequate oxygen levels in the blood. In severe cases, the infection can lead to respiratory failure, requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) to support breathing. The progression of the disease can vary, with some individuals experiencing rapid deterioration. The severity of the infection often depends on the type of virus and the individual's overall health.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-507031-38-00Protocol codeD9185C00001Estimated enrolment2 900 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.